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The present study is the synthesis of new heterocyclic moieties like pyrazole, isoxazole and thiazole containing 
benzimidazole nucleus. The title compounds were synthesized from 4-(1H-benzo[d]imidazol-2-yl) oxazol-2-amine. The 
newly synthesised compounds were screened for their in vitro anti-inflammatory activity and demonstrated excellent to 
moderate activity and molecular docking study reports are supporting anti-inflammatory activity showed high inhibition 
constant and binding energy. The structures of synthesised compounds were characterized by IR, 1HNMR, Mass 
spectroscopic methods.  
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Chemistry of heterocycles is highly essential for the 
present pathogenic environment to address the real-
world demands1,2. Synthesis of heterocyclic 
compounds is a great challenge for higher efficiency 
and eco-friendly point of view3,4. As the quest for 
synthesis of new heterocycles for controlling and 
curing the emerging diseases continues, Scientists 
have paid attention to design and development of 
novel heterocyclic compounds from natural products 
and synthetic methods5,6, Especially nitrogen-
containing heterocyclic compounds are occupying 
unique position in the area of modern drugs and 
pharmaceuticals7,8. Majority of the pharmaceutical 
products are heterocycles which meet the expectations 
of the current industrial and biological requirements. 
In recent days, benzimidazole and its derivatives 
have received great attention in the field of medicinal 
chemistry9-11. The current study involves the synthesis 
of most biodynamic compound benzimidazole 
containing oxazole, thiazole, pyrazole and isoxazole 
which exhibit various biological properties like 
antitumor12, anthelmintic13, anal gesic14, 
antimicrobial15 and antibacterial16 and anti-
inflammatory activity17. Hence, in this direction 
efforts have been undertaken to introduce most 
versatile and biologically active molecules containing 





derivatives which were synthesized from 4-(1H-
Benzo[d]imidazol-2-yl)oxazol-2-amine 
Experimental Section  
Materials and Methods 
The reaction progress was monitored by TLC. IR 
Spectrum of compounds were recorded by KBr pellet 
method using Perkin Elmer BX series and HNMR 
spectrum was recorded by Brucker 400 MHz using 
DMSO used as solvent and TMS used as internal 
standard. Chemical shifts (δ) were expressed in ppm. 
Mass spectrum of compounds were measured on 
GC/MS-QP1000 EX (EI,70 Ev) mass spectrometer. 
Elemental analysis was recorded by using Perkin 
Elmer 240 CHN analyser (Table 1).  
General reaction procedure for Compound 4 
Equimolar mixture of Benzaldehyde (0.004 mol) 
and 4-(1H-benzo[d]imidazol-2-yl)thiazol-2-amine18 
(3) (0.004 mol) were refluxed in ethanol for about 4h
with few drops of glacial acetic acid added. Progress
of the reaction was monitored by TLC. After the
completion of the reaction, it was cooled and the
product was filtered and recrystallized with methanol
to afford the compound Schiff base (2) (Scheme 1).




General reaction procedure for Compound 5  
Equimolar mixture of compound 4 (0.01mol), 
thioglycolic acid (0.01mol), Benzaldehyde (0.01mol) 
in 1,4 dioxane (30 mL), with a pinch of zinc chloride 
was refluxed for about 6.5 hours. After refluxing the 
solution was filtered and cooled in ice bath. Solid 
product was filtered, washed with 10% NaHCO3 
solution and it was recrystallized from alcohol. The 
compounds 3(b-h) were prepared by similar procedure 
with minor changes in reaction conditions (Scheme 1).  
 
(Z)-3-(4-(1H-Benzo[d]imidazol-2-yl) thiazol-2-yl)-5-benzylidene-
2-phenyl thiazolidin-4-one (5a) 
IR (KBr,cm-1): 3325(NH), 1543 (C=N), 1662 
(C=O), 1230 (C=S); 1H NMR (DMSO-d6, 400MHz,  
δ in ppm): 5.92(s,1H,N-CH-Ar), 6.54(s,1H,CH,Ar), 
7.13-7.23(m,4H,Ar-H), 7.25-7.46(m,5H,Ar-H),7.56-
7.76(m,5H, Ar-H), 9.85(bs, 1H,NH). MS, m/z (%), 
466 (M+); Anal.Calcd for C26H17N3OS: C,66.93; 




methylbenzylidine)-2-phenyl thiazolidine -4-one (5b) 
IR(KBr,cm-1): 3337(NH), 2690(C-H), 1560(C=N), 
1672(C=O),1249 (C=S); 1H NMR (DMSO-d6 ,400 
MHz, δ in ppm) : 2.85(s,3H,CH3), 5.66 ( s, 1H,N-CH-
Ar), 6.54 (s,1H,CH,Ar), 7.15-7.24 (m, 4H,Ar-H); 
7.28-7.38(m, 4H,Ar-H), 7.42-7.64 (m, 4H,Ar-H), 
9.95(bs,1H,NH): MS, m/z(%), 480 (M+); Anal.Calcd 
 
Table 1 — Physical data of synthesized compounds 5, 6 and 7 (a-e) 
Compounds 5a 5b 5c 5d 5e 
Ar Ph 4-CH3- Ph 4-OCH3- Ph 4-OH- Ph 4-NO2- Ph 
M.P (C) 250-52 255-57 256-58-26 251-53 258-60 
Yield (%) 78 82 79 80 75 
Compounds 6a 6b 6c 6d 6e 
Ar Ph 4-CH3- Ph 4-OCH3- Ph 4-OH- Ph 4-NO2- Ph 
M.P (C) 255-57 258-60 260-62 259-61 263-65 
Yield (%) 82 78 76 81 74 
Compounds 7a 7b 7c 7d 7e 
Ar Ph 4-CH3- Ph 4-OCH3- Ph 4-OH- Ph 4-NO2- Ph 
M.P (C) 258-60 261-63 264-66 261-63 265-67 










for C27H20N4OS2: C,67.48; H,4.19; N,11.66% Found : 
C,67.08; H,3.90; N,11.05%.  
 
(Z)-3-(4-(1H-Benzo[d]imidazol-2-yl)thiazol-2-yl)-5-(4- 
methoxybenzylidene)-2-phenyl thiazolidin-4-one (5c) 
IR (KBr,cm-1): 33340 (NH), 3045(C-H), 1560 
(C=N), 1684(C=O), 1236 (C=S); 1H NMR (DMSO-
d6,400 MHz, δ in ppm ); 3.45 (s, 3H, OCH3), 5.72 
(s,1H,N-CH-Ar), 6.58 (s,1H,CH,Ar),7.26-7.50 
(m,5H,Ar-H), 7.65-7.84 (m, 4H,Ar-H), 10.05(bs, 
1H,NH); MS, m/z(%), 469 (M+); Anal .Calcd for 
C27H20N402S2: C, 65.30; H, 4.06; N,11.28 %.Found : 





3(C=O),1238(C=S); 1H NMR (DMSO-d6, 400 MHz, 
δ in ppm): 5.88(s,1H, N-CH-Ar), 6.56(s,1H,CH Ar); 
7.14-7.27(m,4H,Ar-H),7.30-7.49(m,5H,Ar-H),7.55-
7.72(m, 4H, Ar-H),10.14 (bs,1H,NH),11.25 (s, 
1H,OH), ;MS, m/z (%), 482 (M+); Anal. Calcd for 
C26H18N4O2S2: C, 64.71; H, 3.76; N, 11.61%. Found: 
C, 64.42; H, 3.42; N, 11.38%. 
 
(Z)-3-(4-(1H-Benzo[d]imidazol-2-yl)thiazol-2-yl)-5-(4- 
nitrobenzylidene)-2-phenyl thiazolidin-4-one (5e) 
IR(KBr,cm-1): 3340(NH),1572(C=N),1525 
(NO2),1683(C=O), 1234 (C=S); 1H NMR (DMSO-
d6,400MHz, δ in ppm): 5.84 (s,1H, N-CH-Ar),6.58 
(s,1H, CH Ar); 7.13-7.26 (m,4H, Ar-H),7.25-
7.48(m,5H, Ar-H), 8.16-8.35 (m,4H, Ar-H),10.20 
(bs,1H,NH), MS, m/z (%), 511 (M+); Anal.Cacld for 
C26H17N5O3S2;C, 61.04; H, 3.35; N, 13.69%. Found: 
C, 60.82; H, 3.06; N, 13.22%. 
 
General reaction procedure for compound 6  
Equimolar mixture of compound 5a (0.03 moL), 
hydrazine hydrate (0.03 moL) and anhydrous sodium 
acetate (0.001 moL) in glacial acetic acid (30 mL) 
was heated under reflux for about 6.5 h, cooled at r.t 
and poured into crushed ice. The solid product was 
filtered, washed with water and recrystallized from 
Ethyl alcohol to afford the pure compound. The 
remaining compounds 4(b-h) were prepared by 
similar procedure with minor changes as per the 




IR (KBr, cm-1): 3348 (NH), 3078 (C-H ring), 
1546(C=N), 1238 (C=S), 1042(N-N); 1H NMR 
(DMSO-d6, 400MHz, δ in ppm):4.85 (d, 1H, CH-N), 
4.62 (d, 1H, CH-S), 5.90 (s,1H,N-CH-Ar),6.56 (s,1H, 
CH Ar); 7.10-7.22(m,4H, Ar-H), 7.26-7.45(m,5H,Ar-
H),7.55-7.78 (m,5H, Ar-H), 9.75 (bs, 1H,NH). MS, 
m/z(%),480 (M+); Anal. Calcd for C26H20N6S2: C, 





IR (KBr, cm-1 ): 3342 (NH),3084(C-H ring), 2963 
(C-H), 1565 (C=N), 1249 (C=S), 1052(N-N); 1H 
NMR (DMSO-d6, 400MHz, δ in ppm): 2.82 
(s,3H,CH3),4.82 (d, 1H, CH-N), 4.60 (d, 1H, CH-S), 
5.81 (s,1H, N-CH-Ar),6.51(s,1H, CH Ar); 7.18-7.26 
(m,4H, Ar-H), 7.28-7.38(m,4H, Ar-H), 7.45-7.68 
(m,4H, Ar-H), 9.98 (bs, 1H,NH).MS, m/z (%), 494 
(M+); Anal. Calcd for C27H22N6S2: C, 65.56; H, 4.48; 




IR (KBr, cm-1) : 3343(NH),3039(C-H),1559(C=N), 
1241 (C=S)1063(NN); 1H NMR (DMSO-d6, 
400MHz, δinppm):3.48(s,3H,OCH3),4.82(d,1H,CH-
N),4.60(d,1H, CH-S),5.74(s,1H,N-CH-Ar),6.58(s,1H, 
CH Ar); 7.21-7.28 (m,4H,Ar-H), 7.31-7.58 (m,5H,Ar-
H), 7.68-7.87(m,4H,Ar-H),10.04(bs,1H,NH), MS, 
m/z (%), 510 (M+); Anal. Calcd for C27H22N6OS2:C, 
63.51; H, 4.34; N, 16.46%. Found: C, 63.31; H, 4.18; 
N, 16.16 %. 
 
4-(6-(4-(1H-Benzo[d]imidazol-2-yl) thiazol-2-yl)-5-phenyl-
3,3a,5,6-tetra hydro-2H-pyrazolo[3,4-d]thiazol-3-yl) phenol (6d) 
IR (KBr, cm-1): 3516(OH), 3352 (NH),1571 
(C=N), 1242 (C=S) 1043 (N-N); 1H NMR (DMSO-d6, 
400 MHz, δ in ppm): 4.72(d,1H,CH-N), 4.61 (d,1H, 
CH-S),5.92(s,1H,N-CH-Ar),6.53(s,1H,CH Ar); 7.18-
7.31(m,4H,Ar-H),7.28-7.52 (m,5H, Ar-H), 7.61-7.74 
(m,4H,Ar-H), 10.15 (bs,1H,NH), 11.35(s, 1H,OH) 
;MS, m/z (%),413(M+);Anal.Calcd for C26H20N6OS2: 
C, 62.88; H, 4.06; N, 16.92%. Found: C, 62.62; H, 
3.86; N, 16.52 %. 
 
6-(4-(1H-Benzo[d]imidazol-2-yl)thiazol-2-yl)-3-(4-nitrophenyl)-5-
phenyl-3,3a,5,6 tetrahydro-2H-pyrazolo[3,4-d] thiazole(6e) 
IR ( KBr, cm-1 ): 3346 (NH), 1575 (C=N), 1528 
(NO2), 1236 (C=S), 1052(N-N); 1H NMR (DMSO-d6, 
400MHz, δ in ppm): 4.91(d,1H,CH-N), 4.75 (d,1H, 
CH-S), 5.88 (s,1H, N-CH-Ar), 6.62(s,1H, CH Ar); 
7.16-7.29 (m,4H, Ar-H), 7.28-7.52 (m,5H, Ar-H), 
8.18-8.41 (m,4H, Ar-H),10.22 (bs,1H,NH),MS, m/z 
(%), 525 (M+); Anal. Calcd for C26H19N7O2S2: C, 




59.41; H, 3.64; N, 18.65 %. Found: C, 59.12; H, 3.35; 
N, 18.34%. 
 
General reaction procedure for compound 7  
Equimolar mixture of compound 3a (0.03 mol), 
hydroxylamine hydrochloride (0.03 mol) and 
anhydrous sodium acetate (0.001 mol) in glacial 
acetic acid (30 mL) was heated under reflux for about 
7h , cooled at r.t and poured in to crushed ice. The 
solid product was filtered, washed with water and 
recrystallized from ethyl alcohol to afford the pure 
compound. The remaining compounds 4(b-h) were 
prepared by similar procedure with minor changes as 




IR (KBr, cm-1): 3348 (NH), 3078 (C-H ring), 
1546(C=N), 1238 (C=S); 1H NMR (DMSO-d6, 
400MHz, δ in ppm):4.95 (d, 1H, CH-O), 4.72 (d, 1H, 
CH-S), 5.90 (s,1H,N-CH-Ar),6.58 (s,1H, CH Ar); 
7.10-7.22(m,4H, Ar-H), 7.26-7.45(m,5H,Ar-H),7.55-
7.78 (m,5H, Ar-H), 9.75 (bs, 1H,NH). MS, m/z (%), 
481 (M+); Anal. Calcd for C26H19N5OS2: C, 64.84; H, 





IR (KBr, cm-1 ): 3342 (NH),3084(C-H ring),  
2963 (C-H), 1565 (C=N), 1249 (C=S) ;  
1H NMR (DMSO-d6, 400MHz, δ in ppm): 2.82 
(s,3H,CH3), 4.98 (d, 1H, CH-O), 4.75 (d, 1H, CH-S), 
5.81 (s,1H, N-CH-Ar),6.61 (s,1H, CH Ar); 7.18-7.26 
(m,4H, Ar-H), 7.28-7.38(m,4H, Ar-H), 7.45-7.68 
(m,4H, Ar-H), 9.98 (bs, 1H,NH).MS, m/z (%),  
495 (M+); Anal. Calcd for C27H21N5S2: C, 65.43; H, 




-5-phenyl-3,3a, 5,6-tetrahydrothiazolo[4,5-c] isoxazole(7c) 
IR (KBr,cm-1):3343 (NH), 3039 (C-H),1559(C=N), 
1241 (C=S); 1H NMR (DMSO-d6, 400MHz, δ in 
ppm): 3.48 (s,3H,OCH3), 5.12(d,1H,CH-O), 4.74 
(d,1H, CH-S), 5.74(s,1H,N-CH-Ar),6.64 (s,1H, CH 
Ar); 7.21-7.28 (m,4H,Ar-H), 7.31-7.58(m,5H,Ar-H), 
7.68-7.87(m,4H, Ar-H), 10.04 (bs,1H, NH), MS, m/z 
(%), 511 (M+); Anal. Calcd for C27H21N5O2S2: C, 
63.38; H, 4.14; N, 13.69%. Found: C, 63.05; H, 4.05; 
N, 13.21%. 
4-(6-(4-(1H-Benzo[d]imidazol-2-yl) thiazol-2-yl)-5-phenyl-
3,3a,5,6-tetra hydrothiazolo[4,5-c]isoxazol-3-yl) phenol (7d) 
IR (KBr, cm-1): 3516(OH), 3352 (NH), 1571 
(C=N), 1242 (C=S); 1H NMR (DMSO-d6, 400 MHz, 
δ in ppm): 5.08 (d,1H,CH-O), 4.72 (d,1H, CH-S), 
5.92 (s,1H, N-CH-Ar), 6.63 (s,1H, CH Ar); 7.18-7.31 
(m,4H,Ar-H), 7.28-7.52 (m,5H, Ar-H), 7.61-7.74 
(m,4H,Ar-H), 10.15 (bs,1H,NH), 11.35 (s, 1H,OH) 
;MS, m/z (%), 497 (M+); Anal. Calcd for 
C26H20N6OS2: C, 62.76; H, 3.85; N, 14.07%. Found: 
C, 62.76; H, 3.85; N, 14.07%. 
 
6-(4-(1H-Benzo[d]imidazol-2-yl)thiazol-2-yl)-3-(4-nitrophenyl) -
5-phenyl-3,3a,5,6-tetra hydrothiazolo [4,5-c]isoxazole(7e) 
 IR ( KBr, cm-1 ): 3346 (NH), 1575 (C=N), 1528 
(NO2), 1236 (C=S); 1H NMR (DMSO-d6,400MHz, δ 
in ppm):5.14 (d,1H,CH-O), 4.85 (d,1H, CH-S), 5.88 
(s,1H, N-CH-Ar),6.65 (s,1H, CH Ar); 7.16-7.29 (m, 
4H, Ar-H), 7.28-7.52 (m,5H, Ar-H), 8.18-8.40 (m,4H, 
Ar-H),10.22 (bs,1H,NH),MS, m/z (%), 526 (M+); 
Anal. Calcd for C26H18N6O3S2: C, 59.30; H, 3.45; N, 
15.96%. Found: C, 58.90; H, 3.15; N, 15.56%. 
 
In vitro Anti-inflammatory activity 
About 5 mL of reaction mixture which contains  
0.2 mL of egg albumin, 2.8 mL of phosphate buffered 
saline (PBS, pH 6.4) was added with 2 mL of 
synthesized compounds at 50 and 100 µg/ml and 
double-distilled water with equal volume was used as 
control. The prepared mixtures were incubated at 
about (37±2)°C in BOD incubator for about 15 min 
and followed by heating at 70°C for about 5 min. 
After attaining the r.t, absorbance was measured at 
660 nm using vehicle as blank and viscosity was 
determined by Ostwald viscometer. Diclofenac 
sodium was used as standard drug19 and its 
concentrations were maintained at 50 and 100 µg/mL 
(Table 2). 
The inhibition (%) of protein denaturation was 
measured by using the following formulae  
 
% of inhibition = 100 × (Vt/Vc-1)  
 
Where Vt = Test sample absorbance Vc= Absorbance 
of control 
The concentration of drug for 50% inhibition (IC50) 
was determined by plotting % of inhibition with 
respect to control against treatment concentration. 
Each value in the table is represented as mean ± SD 
(n = 3). Values in the same column followed by a 
different letter (a-e) are significantly different (p < 
0.05).  




Inhibitions of protein denaturation of the 
compounds are shown in the descending order: 
7e>6e>7c>7d>6c>7b>6d>7a>6b>6a> 
 
In Silico anti-inflammatory studies 
The docking studies was done by using the 
molecular docking server20,21. The cyclooxygenase 
enzyme was downloaded from the PDB(Protein data 
bank) and was docked to the title compound and the 
results are tabulated given below. 
 
Docking studies of 6-(4-(1H-benzo[d]imidazol-2-yl) thiazol-2-
yl)-3,5-diphenyl-3,3a,5,6-tetrahydro-2H-pyrazolo [3, 4-d] 
thiazole (6a):  
Docking studies of6-(4-(1H-benzo[d]imidazol-2-yl) thiazol-2-
yl)-3, 5-diphenyl-3, 3a, 5, 6-tetrahydrothiazolo [4, 5-c] 
Isoxazole ( 7a):  
 
Results and Discussion  
The present investigation is the synthesis of new 
biheterocyclic rings that are thiazole-pyrazole and 
thiazole-isoxazole derivatives are linked at 2nd position 
of benzimidazole in an appreciable yield. The 
compound 4 (Schiff’s base) was synthesized by using 
2-aminobenzimidazole with benzaldehyde under 
simple procedure. The compound 5 (Chalcone 
derivatives of thiazolidinone) was synthesized by 
cyclization of one pot three -component method using 
compound 4, thioglycolic acid and substituted aromatic 
aldehydes using anhydrous zinc chloride22. Later, the 
intermediate compound 5 undergoes cyclization with 
hydrazine hydrate affords the compound 6 with 
pyrazole ring. Whereas, intermediate compound 5 
undergoes cyclization with hydroxyl amine 
hydrochloride in the presence of anhydrous acetic acid 
to afford the compound 7 with isoxazole ring.  
The structures of newly synthesized compound  
were confirmed based on spectral and analytical data. 
The compounds showed IR absorption bands at 3348 
cm-1 (NH), 1564 cm-1 (C=N), 1238 cm-1(C=S), 1042 
cm-1 (N=N), 1680 cm-1 (C=O) respectively. 1H NMR 
Spectra of title compounds showed singlet signals at 
5.58 for N-CH-S, singlet thiazole protein signals at 
6.56, doublet signals at 4.62 CH-S, 4.82 CH-N and 
9.82 singlet proton for NH and also phenylic protons as 
multiplet in the range of 7.10-8.41 ppm respectively. 
Mass spectra of synthesized compounds showed a 
molecular ion peak at m/z corresponding molecular 
weights. 
 
In vitro anti-inflammatory activity  
The synthesized derivatives were tested for their 
efficacy to inhibit the protein denaturation. The 
process is carried out by using egg albumin. All the 
compounds showed concentration dependent 
inhibition property. Compounds (7e and 6e) are found 
to exhibit significant inhibition percentage compared 
to other synthesized compounds. Nevertheless, 
Compounds (7c, 6c, 6e and 7e) are competed in 
exhibiting a notable activity with good inhibition 
percentage shown in Table 2. On the other hand, the 
compounds 6d and 7d showed moderate activity. The 
variations in the activity might be due to different 
functional groups present in derivatives. By these 
studies, it is concluded that benzimidazole derivatives 
showed preliminary anti-inflammatory activity.  
The IC50 values represented in Table 3 are shown 
as mean ±SD. According to the data, the IC50 24±0.1, 
21±0.5 of compounds 7c and 6d are significant and are 
comparable with standard Diclofenac sodium standard.  
 
In silico anti-inflammatory activity  
Molecular docking studies have shown that the 
ligand 1 has shown a binding energy of-6.06 kcal/mol 




Table 2 — In vitro anti-inflammatory activity of compounds (6a-e) and (7a-e) percentage of inhibition (%) 
Compounds  6a 6b 6c 6d 6e 7a 7b 7c 7d 7e Standard 
Conc. (µg/mL)  50 40 41 44 43 45 42 43 44 43 46 48 
100 74 75 78 76 85 75 77 84 83 88 90 
 
Table: 3 — In vitro anti-inflammatory activity of compounds (6a-e) and (7a-e) percentage of inhibition in IC 50 (%) 
Compounds  6a 6b 6c 6d 6e Standard 
IC 50 5.1±2.4 6.5±2.3 7.9±0.5 21±0.5 17±1.0 28 ± 0.5 
Compounds  7a 7b 7c 7d 7e Standard 
IC 50 10.±1.5 09±0.7 24±0.1 15.±2.3 14.5±2.1 32±0.5 
 
Table 4 — Free energy of binding between the enzyme and the ligand 1 












-6.06 kcal/mol 36.07 uM -7.15 kcal/mol -0.04 kcal/mol -7.19 kcal/mol 50% 689.87 
 




the enzyme and the ligand 1where different amino 
acids bind to the active site of the ligand. Interaction 
table the various types of interactions between the 
amino acids of the enzyme and the ligand 1 are shown 
in Table 5 where the major amino acids involved in 
binding are gluatamic acid, cysteine, tyrosine, 
glutamine and threonine at the active site. Docking 
studies between the ligand 2 has shown a binding 
energy of -6.40 kcal/mol (Table 6). Figure 2 shows 
the docking pose between the enzyme and the ligand 
2 where various amino acids bound to the active site 
of the ligand. Interaction table the various types of 
interactions between the amino acids of the enzyme 
and the ligand 1 are shown in Table 7 where the major 
amino acids involved in binding are tyrosine, 
glutamic acid, glutamine, cysteine and lysine. 
 
 
Fig. 1 — Docking pose showing the interaction between the enzyme and the ligand 1 
 
Table 5 — Interaction table the various types of interactions between the aminoacids of the enzyme and the ligand 1 


































N4 (15) [3.63]  
– 







      C11 (16) [3.23] – GLU67 (CB, CD, CG, 
OE1, OE2) 
         C9 (12) [3.69] – GLU67 (CB) 
         N3 (11) [2.93] – GLU67 (CB) 
         N2 (9) [3.69] – GLU67 (CB) 
         C12 (17) [3.38] – GLU67 (CD, CG, OE2) 
         N5 (20) [3.11] – GLU67 (CD, CG) 
         C22 (30) [3.77] – GLU67 (CG) 
         N6 (21) [3.41] – GLU67 (CD) 
         H9 (43) [3.08] – GLU67 (CD) 
GLU67 (OE2) 
         C14 (22) [3.48] – GLU67 (OE2) 
         C15 (23) [3.32] – GLU67 (OE2) 
         C17 (25) [3.28] – GLU67 (OE2) 
         C3 (3) [3.42] – THR71 (CG2) 
         C2 (2) [3.19] – THR71 (CG2) 
         C1 (1) [3.69] – THR71 (CG2) 
 




Compared with ligand 1, ligand 2 has higher free 
energy of binding and could act as a better anti-
inflammatory compound.  
 
Conclusion 
It has been concluded that new analogues of 
pyrazolo-thiazoles and isoxazole-thiazoles linked with 
benzimidazole nucleus is a novel method. In the 
present work that the title compounds are exhibiting 
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Fig. 2 — Docking pose showing the interaction between the enzyme and the ligand 2 
 
Table 6 — Free energy of binding between the enzyme and the ligand 2 












-6.40 kcal/mol 20.35 uM -6.93 kcal/mol -0.51 kcal/mol -7.43 kcal/mol 50% 568.269 
 
Table 7 — Interaction table the various types of interactions between the aminoacids of the enzyme and the ligand 2 
Hydrogen 
bonds 
  Polar   Hydrophobic   pi-pi   other   
N5 (20) 
[3.12] 
– TYR55  
(CD2, CE1, CE2, 















– GLN54 (CB) 
N4 (15) 
[3.24] 
– GLU67  
(CD, OE2) 










– GLN54 (CB) 
N5 (20) 
[3.35] 
– GLU67  
(CD, CG, OE2) 









– GLU67 (OE2)          C17 (24) [3.81] – LYS56 (NZ) 
            C22 (29)[3.48] – LYS56 (NZ) 
            O1 (21) [3.88] – CYS57 (SG) 
            C12 (16) [3.28] – GLU67 (CD, 
CG, OE2) 
            C13 (17) [3.45] – GLU67 (CG) 
            O1 (21) [3.29] – GLU67 (CG) 
            C23 (30) [3.39] – GLU67 (CD, 
OE1, OE2) 
            C24 (31) [3.68] – GLU67 (OE1)
            C9 (12) [3.20] – GLU67 (OE2)
            C8 (10) [3.89] – GLU67 (OE2)
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